Form 8-K - Current report:
SEC Accession No. 0001193125-24-056966
Filing Date
2024-03-04
Accepted
2024-03-04 08:40:59
Documents
16
Period of Report
2024-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d762406d8k.htm   iXBRL 8-K 32743
2 EX-4.1 d762406dex41.htm EX-4.1 72559
3 EX-10.1 d762406dex101.htm EX-10.1 168335
  Complete submission text file 0001193125-24-056966.txt   464634

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nktr-20240304.xsd EX-101.SCH 2835
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nktr-20240304_lab.xml EX-101.LAB 17235
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nktr-20240304_pre.xml EX-101.PRE 10802
18 EXTRACTED XBRL INSTANCE DOCUMENT d762406d8k_htm.xml XML 3539
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 24712972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)